Lutetium-177 PSMA-617 (Pluvicto)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Lutetium-177 PSMA-617 (Pluvicto), covering 2024-12-06 to 2025-07-11. Get the full timeline:
Most recent: Clinical Trial Update: In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy [Phase 2]